Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-CLL1 CAR-T cells (920th Hospital)
- Development stage
- Unknown
- Lead developer
- 920th Hospital of Joint Logistics Support Force
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting C-type lectin-like molecule-1 (CLL1, also known as CLEC12A). Developed by the 920th Hospital of Joint Logistics Support Force of the People's Liberation Army of China, the therapy is designed for the treatment of relapsed or refractory acute myeloid leukemia (AML). CLL1 is a surface antigen highly expressed on AML blasts and leukemic stem cells but minimally expressed on normal hematopoietic stem cells, providing a therapeutic window to minimize myelosuppression. The treatment process involves engineering a patient's own T cells to express a CAR that specifically recognizes CLL1, enabling these modified cells to identify and eliminate CLL1-positive leukemia cells upon re-infusion. It is currently in Phase 1 clinical development to assess safety, efficacy, and pharmacokinetics.
- Other names
- Autologous anti-CLL1 CAR-T cellsAnti-CLL1 CAR-TAnti-CLL-1 CAR-TAnti-CLL 1 CAR-T
02
Targets
CLEC12A
Beyond the preview
Go deeper on Anti-CLL1 CAR-T cells (920th Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-CLL1 CAR-T cells (920th Hospital).